

Prefrontal Cortex Regulates Chronic Stress-Induced Cardiovascular Susceptibility

Derek Schaeuble, BS; Amy E. B. Packard, PhD; Jessica M. McKlveen, PhD; Rachel Morano, BS; Sarah Fourman, BS; Brittany L. Smith, PhD; Jessie R. Scheimann, PhD; Benjamin A. Packard, BS; Steven P. Wilson, PhD; Jeanne James, MD; David Y. Hui, PhD; Yvonne M. Ulrich-Lai, PhD; James P. Herman, PhD; Brent Myers, PhD

Background—The medial prefrontal cortex is necessary for appropriate appraisal of stressful information, as well as coordinating visceral and behavioral processes. However, prolonged stress impairs medial prefrontal cortex function and prefrontal-dependent behaviors. Additionally, chronic stress induces sympathetic predominance, contributing to health detriments associated with autonomic imbalance. Previous studies identified a subregion of rodent prefrontal cortex, infralimbic cortex (IL), as a key regulator of neuroendocrine-autonomic integration after chronic stress, suggesting that IL output may prevent chronic stress-induced autonomic imbalance. In the current study, we tested the hypothesis that the IL regulates hemodynamic, vascular, and cardiac responses to chronic stress.

Methods and Results—A viral-packaged small interfering RNA construct was used to knockdown vesicular glutamate transporter 1 (vGluT1) and reduce glutamate packaging and release from IL projection neurons. Male rats were injected with a vGluT1 small interfering RNA-expressing construct or GFP (green fluorescent protein) control into the IL and then remained as unstressed controls or were exposed to chronic variable stress. IL vGluT1 knockdown increased heart rate and mean arterial pressure reactivity, while chronic variable stress increased chronic mean arterial pressure only in small interfering RNA-treated rats. In another cohort, chronic variable stress and vGluT1 knockdown interacted to impair both endothelial-dependent and endothelial-independent vasoreactivity *ex vivo*. Furthermore, vGluT1 knockdown and chronic variable stress increased histological markers of fibrosis and hypertrophy.

Conclusions—Knockdown of glutamate release from IL projection neurons indicates that these cells are necessary to prevent the enhanced physiological responses to stress that promote susceptibility to cardiovascular pathophysiology. Ultimately, these findings provide evidence for a neurobiological mechanism mediating the relationship between stress and poor cardiovascular health outcomes. (*J Am Heart Assoc.* 2019;8:e014451. DOI: 10.1161/JAHA.119.014451.)

Key Words: blood pressure • heart rate • heart-brain relationships • vascular function

Stress, a real or perceived threat to homeostasis or well-being, elicits behavioral and physiological responses to promote organismal adaptation.^{1,2} However, prolonged stress

exposure has deleterious effects on health, increasing susceptibility to cardiovascular, psychiatric, and metabolic disorders.^{3–6} In fact, chronic psychosocial stress predicts the incidence of cardiovascular disease, cardiac-related morbidity and mortality, and doubles the risk of myocardial infarction.^{7,8} Exaggerated heart rate (HR) reactivity to acute stress also predicts poor cardiovascular outcomes, including hypertension, ventricular hypertrophy, and atherosclerosis.⁹ Although the biological mechanisms mediating the relationship between stress and cardiovascular health are not completely understood, adverse outcomes likely result from prolonged exposure to neural and endocrine stress mediators.

The initial appraisal of psychological stressors largely occurs in the limbic system, a network of interconnected structures spanning the forebrain. The medial prefrontal cortex (mPFC) is a key limbic cortical structure mediating stress appraisal, emotion, and cognition.^{10–13} Moreover, activity within a specific region of the ventral mPFC, the subgenual cingulate cortex (BA25), associates with sadness in healthy controls,¹⁴ as well as

From the Biomedical Sciences, Colorado State University, Fort Collins, CO (D.S., B.M.); Pathology and Laboratory Medicine (A.E.B.P., S.F., D.Y.H.), and Pharmacology and Systems Physiology (R.M., B.L.S., J.R.S., B.A.P., Y.M.U.-L., J.P.H.), University of Cincinnati, OH; National Institutes of Health, National Center for Complementary and Integrative Health, Bethesda, MD (J.M.M.); Pharmacology, Physiology, and Neuroscience, University of South Carolina, Columbia, SC (S.P.W.); Division of Cardiology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI (J.J.).

Correspondence to: Brent Myers, PhD, Department of Biomedical Sciences, Colorado State University, 1617 Campus Delivery, Fort Collins, CO 80523. E-mail: brent.myers@colostate.edu

Received August 28, 2019; accepted November 5, 2019.

© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Clinical Perspective

What Is New?

- Knockdown of glutamate release from infralimbic cortex increases heart rate and arterial pressure reactivity.
- Decreased infralimbic glutamate output leads to vascular dysfunction after chronic stress.
- These functional changes associate with histological indicators of cardiac hypertrophy, as well as vascular hypertrophy and fibrosis.

What Are the Clinical Implications?

- These studies provide a neurobiological mechanism that may account for the link between long-term stress and increased cardiovascular disease risk.

pathological depression in treatment-resistant patients.¹⁵ Recent human neuroimaging studies have also identified the ventral mPFC as a component of the central autonomic network that responds to and coordinates visceral functions, including stress-evoked blood pressure reactivity.^{16–19} The rodent homolog of BA25 is infralimbic cortex (IL).^{20–22} This subregion of ventral mPFC provides inputs to stress-integrative nuclei, including the posterior hypothalamus and brainstem autonomic centers.^{23–26} Our previous studies reduced glutamate outflow from the IL in rats undergoing chronic variable stress (CVS) and found hyperactivation of the hypothalamic-pituitary-adrenal axis.^{27,28} As glutamate release from IL projections is a key regulator of acute and chronic neuroendocrine reactivity, we hypothesized that IL output may prevent chronic stress-induced autonomic imbalance and associated cardiovascular susceptibility.

To address this hypothesis, a lentiviral-packaged small interfering RNA (siRNA) targeting vesicular glutamate transporter 1 (vGluT1) was injected in the IL. This approach selectively reduces vGluT1 expression in IL glutamate neurons, preventing the packaging and release of glutamate from pre-synaptic terminals.^{28–30} Animals were then exposed to CVS to examine interactions between chronic stress and hypo-functionality of ventral mPFC in terms of cardiovascular reactivity, arterial function, and remodeling of the vasculature and myocardium. These studies identified the necessity of the IL for reducing hemodynamic, vascular, and cardiac consequences of prolonged stress. Additionally, this work points toward a neurobiological mechanism mediating the relationship between stress and cardiovascular health.

Methods

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Animals

Adult male Sprague-Dawley rats were obtained from Harlan (Indianapolis, IN) with weights ranging from 250 to 300 g. Rats were housed individually in shoebox cages in a temperature- and humidity-controlled room with a 12-hour light-dark cycle (lights on at 6:00 AM, off at 6:00 PM) and food and water ad libitum. All procedures and protocols were approved by the University of Cincinnati Institutional Animal Care and Use Committee (protocol: 04-08-03-01) and complied with the National Institutes of Health *Guidelines for the Care and Use of Laboratory Animals*. The cumulative sequence of procedures used in the current experiments received veterinary consultation and all animals had daily welfare assessments by veterinary and/or animal medical service staff. Signs of poor health and/or weight loss $\geq 20\%$ of presurgical weight were a priori exclusion criteria. These criteria were not met by any animals in the current experiments.

Experiment 1

Design

For experiment 1, 32 rats ($n=8/\text{group}$) were injected with either a lentiviral-packaged construct coding for vGluT1 siRNA or GFP (green fluorescent protein) as a control. After instrumentation with radiotelemetry devices, half of the animals were exposed to 14 days of CVS with the rest of the animals remaining as No CVS controls. All treatment assignments were randomized. Home cage cardiovascular parameters were continuously monitored in all rats throughout the 14-day period of CVS. On the morning of day 15, all rats were subject to an acute novel restraint to examine hemodynamic stress reactivity.

Viral construct

A lentivirus transfer vector, based on a third-generation, self-inactivating transfer vector was constructed as previously described.^{25,28} Briefly, a 363-bp piece of DNA from the rat vGluT1 complementary DNA was synthesized that included 151 bp of the 3' coding region and 212 bp of the 3' untranslated region. This corresponds to nucleotides 1656 to 2018 of GenBank accession No. NM_053859. This is a region of low homology with vGluT2 and vGluT3 and avoids all the putative transmembrane domains of the transporter. The fragment was cloned in antisense orientation into a lentivirus transfer vector that expressed an enhanced GFP reporter. This vector uses the phosphoglycerate kinase-1 promoter, which expresses well in rat brain and is primarily neuronal.^{28,31} A control virus was constructed similarly, using a transfer vector with the phosphoglycerate kinase-1 promoter driving expression of enhanced GFP alone.

Stereotaxic Surgery

Animals were anesthetized (90 mg/kg ketamine and 10 mg/kg xylazine, intraperitoneal) followed by analgesic (2 mg/kg butorphanol, subcutaneous) and antibiotic (5 mg/kg gentamicin, intramuscular) administration. Rats received bilateral 1- μ L microinjections (5×10^6 tu/ μ L titer) into the IL (2.9 mm anterior to bregma, 0.6 mm lateral to midline, and 4.2 mm ventral from dura), as described previously,^{23,28,32} of either the vGluT1 siRNA virus or GFP control. All injections were performed with a 25-gauge, 2- μ L microsyringe (Hamilton, Reno, NV) using a microinjection unit (Kopf, Tujunga, CA) at a rate of 5 minutes/ μ L. To reduce tissue damage and allow diffusion, the needle was left in place for 5 minutes before and after injections. Animals recovered for 6 weeks before commencing experiments, corresponding to timeframes previously used for similar lentiviral systems.^{28,33}

Telemetry

Four weeks after stereotaxic surgery, rats were implanted with radiotelemetry transmitters (PA-C40; Data Sciences International, St. Paul, MN) as previously described.^{34,35} Briefly, animals were anesthetized with inhaled isoflurane anesthesia (1%–5%). The descending aorta was exposed via an abdominal incision, allowing implantation of a catheter extending from the transmitter. The catheter was secured with tissue adhesive (Vetbond; 3M Animal Care Products, St. Paul, MN) and a cellulose patch. The transmitter body was then sutured to the abdominal musculature, followed by suturing of the abdominal musculature and closure of the skin with wound clips. Rats recovered for 2 weeks before wound clips were removed and experiments began.

Chronic variable stress

CVS was comprised of twice daily (AM and PM) repeated and unpredictable stressors presented in a randomized manner, including exposure to a brightly-lit open field (1 m², 5 minutes), cold room (4°C, 1 hour), forced swim (23–27°C, 10 minutes), brightly-lit elevated platform (0.5 m, 5 minutes), shaker stress (100 rpm, 1 hour), and hypoxia (8% oxygen, 30 minutes). Additionally, overnight stressors were variably included, composed of social crowding (6–8 rats/cage, 16 hours) and restricted housing (mouse cage, 16 hours). All animals went through the CVS paradigm concurrently. To prevent body weight differences between stress conditions, rats remaining unstressed in the home cage were food restricted in accordance with the reduced food intake induced by CVS.^{34,36} During the 2 weeks of CVS, unstressed animals received 80% of a food allotment before lights off and the other 20% after lights on to reduce the potential for fasting.^{34,36} On day 15, all rats were exposed to a novel acute restraint to directly compare the effects of vGluT1 knockdown on cardiovascular responses to acute and chronic stress.

Acute stress

The morning after completion of CVS (\approx 16 hours after the last stress exposure), all animals were subjected to a novel 40-minute restraint. Stress response assessment was initiated between 08:00 and 09:00 AM. Animals were placed in well-ventilated Plexiglass restraint tubes with baseline pressure and HR measurements collected in the 1-hour period preceding restraint. After restraint, rats were returned to their home cage with pressure and HR recorded for 60 minutes after restraint.

Tissue collection

After acute restraint, all animals were euthanized with sodium pentobarbital (\geq 200 mg/kg, intraperitoneal) and transcardially perfused with 0.9% saline followed by 4% phosphate-buffered paraformaldehyde. Brains were post-fixed in paraformaldehyde for 24 hours and then stored in 30% sucrose at 4°C. Brains were subsequently sectioned (30 μ m-thick coronal sections) and processed for GFP immunohistochemistry to determine microinjection spread.

Immunohistochemistry

For single immunolabeling of GFP, tissue sections were washed in 50 mmol/L KPBS (potassium phosphate-buffered saline) and incubated in blocking buffer (50 mmol/L KPBS, 0.1% bovine serum albumin, and 0.2% TritonX-100) for 1 hour at room temperature. Sections were placed in rabbit anti-GFP primary antibody (1:1000 in blocking buffer; Invitrogen, La Jolla, CA) overnight at 4°C. Following incubation, sections were rinsed and placed into Alexa488-conjugated donkey anti-rabbit immunoglobulin G (1:500 in blocking buffer; Jackson ImmunoResearch, West Grove, PA) for 30 minutes. Sections were rinsed, mounted onto slides, and cover slipped. Dual fluorescent immunolabeling was performed as described previously,²⁸ with GFP labeled in sequence with vGluT1. vGluT1 was visualized with rabbit anti-vGluT1 primary antibody (1:1000; Synaptic Systems, Goettingen, Germany) followed by Cy3-conjugated donkey anti-rabbit immunoglobulin G (1:500; Jackson ImmunoResearch, West Grove, PA).

Microscopy

For visualization of GFP and vGluT1 co-localization, digital images were captured from a 1-in-12 series with a Zeiss Axio Imager Z2 microscope using optical sectioning (63 \times objective) to permit co-localization within a given z-plane (0.5- μ m thickness). Co-localizations were defined as white fluorescence from overlap between labeled GFP terminals and magenta-colored vGluT1. For each figure, brightness and contrast were enhanced uniformly using Adobe Photoshop (CC 14.2).

Data analysis

Data are expressed as mean \pm SEM. Quantification was conducted by experimenters masked to conditions. All

analyses were conducted using GraphPad Prism (version 7.04) for 2-way ANOVA, R Studio (version 3.4.2) for 3-way repeated measures ANOVA, or Dataquest A.R.T. (version 4.3) for telemetry analysis. Over the course of CVS, activity, HR, arterial pressures, and pulse pressure were sampled in the home cage. Samples were collected during the light phase from 06:00 to 08:00 AM (before the first stressor of the day) and during the dark phase from 7:00 to 9:00 PM (at least 2 hours after the second stressor of the day). During each 2-hour time period, samples were averaged into 10-minute bins for analysis. Beginning the day before CVS, circadian curves were generated for each parameter over the 15-day period. Circadian measures were not normally distributed and were analyzed with the non-parametric Friedman test followed by Dunn multiple comparison. Acute restraint data over time were analyzed by 3-way repeated measures ANOVA; with viral treatment, stress, and time (repeated) as factors. When significant main effects were reported, ANOVA was followed by Tukey post-hoc test to identify specific group differences. Area under the curve (AUC) for the 15 days of CVS or 100 minutes of acute stress was calculated by summing the average values acquired between 2 time points multiplied by the time elapsed $[\Sigma((\text{Time } 1 + \text{Time } 2)/2) \times \text{Time elapsed}]$. Statistical significance for cumulative measures was determined by 2-way ANOVA with treatment and stress as factors. ANOVA was followed by Tukey post-hoc tests in the case of significant main effects. Values >2 SD from the mean were removed as outliers. No animals were removed from the study as outliers but specific time points for telemetry recordings were identified as outliers based on deviation from the mean. These exclusion criteria were developed a priori and applied uniformly. The excluded data points were found to represent non-physiological parameters (eg, HR <200 bpm). Statistical significance was reported as ($P < 0.05$) for all tests.

Experiment 2

Design

Experiment 2 used a similar design as experiment 1. Male rats ($n=7$ /group) received IL injections of lentiviral-packaged vGluT1 siRNA or GFP and experienced CVS or remained unstressed. All treatment assignments were randomized. On day 15, thoracic aorta was collected to examine vasoreactivity and histology. Additionally, hearts and brains were collected for histological analyses.

Chronic variable stress

For experiment 2, CVS was staggered based on the throughput of vascular function experiments. Seven cohorts ($n=4$ animals/cohort, one animal for each treatment group) began the CVS paradigm 1 day apart so that each cohort of 4 would

have tissue collected on successive days. All rats undergoing CVS in experiment 2 received the same stressors in the same sequence. The CVS paradigm was similar to experiment 1, except for the substitution of restraint (30 minutes) for crowding.

Tissue collection

The morning of day 15, ≈ 16 hours after the last stress exposure, all animals were rapidly anesthetized with isoflurane (5%) and decapitated. Thoracic aorta was collected by dissecting 4 mm of aortic tissue proximal to the diaphragm for vascular function analysis. Additional aortic tissue was collected proximal to the initial sample and post-fixed in paraformaldehyde for histological analysis. Hearts were also collected and post-fixed in paraformaldehyde for histological analysis. Brains were post-fixed and subsequently sectioned and processed for GFP immunohistochemistry to determine microinjection spread as described for experiment 1.

Vascular function

Aortic tissue samples were processed for wire myographic vasoreactivity analyses as previously described.³⁷ Briefly, vessels were kept in warm, oxygenated Krebs's solution with connective tissue and adipose removed under a dissecting microscope. Aortic rings were then placed on wires in organ baths (Radnoti, Covina, CA), equilibrated, and brought to tension. Vasoconstriction was assessed in response to increasing concentrations of the endothelial-dependent potassium chloride (KCl; 0 to 50 mmol/L) and endothelial-independent phenylephrine (1×10^{-6} to 1×10^{-2} mmol/L). Vessels were then set to 80% of maximum phenylephrine-induced constriction and relaxation was determined in response to endothelial-dependent acetylcholine (1×10^{-6} to 1×10^{-2} mmol/L) and endothelial-independent sodium nitroprusside (1×10^{-7} to 3×10^{-3} mmol/L). At the end of the experiment, all vessels were weighed and measured (length, circumference, and area) to verify equal dimensions across all groups.

Histology and microscopy

Cardiac and aortic tissue was processed by the Cincinnati Children's Hospital Medical Center Research Pathology Core. Briefly, aortas were paraffin-embedded, sectioned (5 μm), and stained. Verhoeff-Van Gieson (VVG) was used to quantify elastin in the tunica media and Masson Trichrome to quantify collagen in the tunica adventitia as previously described.^{35,37} Paraffin-embedded hearts were oriented for 4-chamber view, sectioned (5 μm), and stained with Masson Trichrome to visualize collagen and wheat germ agglutinin (WGA) conjugated to Alexa488 to visualize myocyte cell membranes as previously described.^{37,38} Vascular and heart tissue were imaged with a Zeiss AxioObserver microscope using a color camera and 10 \times objective.




Figure 1. The spread of individual lentiviral injections was traced on photomicrographs and overlaid onto atlas templates from Swanson⁴⁰ to depict the localization of vesicular glutamate transporter 1 knockdown in experiment 1 (A). Lentiviral injections targeted to the infralimbic cortex with minimal spread to the prelimbic cortex (B). White arrows indicate dorsal and ventral boundaries of the infralimbic cortex. Immunolabeling of green fluorescent protein (green) and vesicular glutamate transporter 1 (magenta) indicated a high degree of co-localization (white arrows) on infralimbic cortex projections in green fluorescent protein controls (C). Knockdown of vesicular glutamate transporter 1 with small interfering RNA treatment decreased vesicular glutamate transporter 1 co-localization with green fluorescent protein on infralimbic cortex projections (D). Scale bars: (B) 100 μm , (C,D) 10 μm . Numbers indicate distance rostral to bregma in millimeters. AC indicates anterior cingulate; fa, anterior forceps of the corpus callosum; IL, infralimbic cortex; PL, prelimbic cortex.

Data analysis

Data are expressed as mean \pm SEM. Quantification was conducted by experimenters blind to conditions. All analyses were conducted using GraphPad Prism (version 7.04) for 2-way ANOVA, R Studio (version 3.4.2) for 3-way repeated measures ANOVA, or Fiji (version 1.51N) for histological quantification. Vasoreactivity data were analyzed by 3-way repeated measures ANOVA; with viral treatment, stress, and drug concentration (repeated) as factors. When significant main effects were reported, ANOVA was followed by Tukey post-hoc test to identify specific group differences. Fiji (version 1.51N) was used to quantify lumen and tunica media dimensions in VVG-stained aorta, as well as adventitia dimensions in Masson Trichrome-stained tissue. Fiji was also used to quantify collagen density in hearts stained with Masson Trichrome. For each animal, 6 sections of aorta or heart were quantified and averaged. To determine myocyte

surface area, Fiji was used to binarize myocyte images. This technique produced dark cytoplasm and bright membranes in cardiomyocytes.³⁹ The dark cytoplasm was used to calculate surface areas of the myocytes in the apex and lateral wall of the left ventricle. For each animal, \approx 100 cells were counted from 6 heart sections and averaged. Statistical significance for histological measures was determined by 2-way ANOVA with treatment and stress as factors. ANOVA was followed by Tukey post-hoc tests in the case of significant main effects. Statistical significance was reported as ($P<0.05$) for all tests.

Results

vGluT1 Knockdown

Injections of a lentiviral-packaged construct expressing vGluT1 siRNA were targeted to the IL (Figure 1A and 1B).⁴⁰ Viral injections were largely limited to the deep layers of IL,

Table 1. Body Weight and Food Intake Throughout Chronic Variable Stress

	Group	Body Weight CVS Day 1 (g)	Body Weight CVS Day 13 (g)	Daily Food Intake (g)
Experiment 1 n=8/group	No CVS GFP	389.78±6.21	405.06±6.14	21.04±0.36
	No CVS siRNA	389.84±12.23	405.85±12.13	21.68±0.53
	CVS GFP	402.03±7.45	404.19±8.57	18.82±0.30*
	CVS siRNA	417.16±6.79	417.64±6.25	18.89±0.35 ^{†,‡}
Experiment 2 n=7/group	No CVS GFP	372.83±7.72	363.80±7.15	15.08±0.45
	No CVS siRNA	379.19±5.03	368.00±4.73	15.35±0.29
	CVS GFP	381.44±9.07	378.10±9.33	17.44±0.53*
	CVS siRNA	384.69±5.10	379.49±3.64	17.78±0.35 ^{†,‡}

Body weight of animals at the beginning and end of chronic variable stress for experiments 1 and 2. In both experiments, CVS rats had ad libitum access to chow while No CVS animals received mild food restriction to prevent significant differences in body weight between chronically stressed animals and controls. CVS indicates chronic variable stress; GFP, green fluorescent protein; siRNA, small interfering RNA.

* $P<0.05$ CVS GFP vs No CVS GFP, [†] $P<0.05$ CVS siRNA vs No CVS GFP, [‡] $P<0.05$ CVS siRNA vs No CVS siRNA.

with minimal spread to the prelimbic cortex (PL). Injections that spread significantly outside the IL (affecting >20% of the PL) or injections that did not show somatic GFP labeling as evidence of successful transduction were removed from the study and all analyses. Within in each experiment, 2 animals were excluded because of failed injections. We have previously shown that the vGluT1 siRNA approach reduces vGluT1 mRNA specifically in the IL, as well as vGluT1 protein co-localization with GFP-labeled terminals.²⁸ In the current study, tissue from rats injected with a GFP control construct exhibited substantial co-localization with vGluT1 protein on cortico-cortical axonal processes (Figure 1C). IL projections transduced with the vGluT1 siRNA construct had reduced co-localization with vGluT1 protein (Figure 1D).

Body Weight and Food Intake

Chronic stress reduces food intake and body weight gain, leading to significant differences in body composition compared with control animals.^{27,28,34,41} As this may confound results related to HR and blood pressure reactivity,³⁴ animals in the No CVS groups for both experiments 1 and 2 received mild food restriction to match body weight with CVS rats (Table 1). In both experiments, there were no significant differences in body weight between groups. However, food restriction in experiment 1 led to food consumption that was significantly greater than the CVS groups [$F(1,28)=31.24$, $P<0.0001$]. In experiment 2, food restriction significantly decreased food intake compared with CVS groups [$F(1,24)=33.25$, $P<0.0001$].

Experiment 1

Circadian behavioral activity

Home cage radiotelemetry data were analyzed for 15 days beginning the day before CVS. Friedman test of circadian

activity (n=7–8/group) found no significant group differences (Friedman statistic=4.040, $P=0.257$). In addition to overnight social crowding on day 2 (Figure 2A), rats experienced overnight housing in mouse cages days 6 and 10. Subsequent 2-way ANOVA analysis of cumulative activity counts (No CVS GFP: 801.88±1.04, No CVS siRNA: 819.29±8.08, CVS GFP: 683.66 ±1.38, CVS siRNA: 860.81±4.46) found significant effects of treatment [$F(1,27)=338.60$, $P<0.0001$], stress [$F(1,27)=60.38$, $P<0.0001$], and a treatment x stress interaction [$F(1,27)=261.9$, $P<0.0001$]. Tukey post-hoc test indicated that total activity over 15 days was lower in CVS GFP rats compared with No CVS GFP ($P<0.0001$). In contrast, cumulative activity was increased in CVS siRNA rats compared with all other groups ($P<0.0001$).

Circadian heart rate

Friedman test of home cage HR (Figure 2B, n=8/group) found significant group differences (Friedman statistic=37.59, $P<0.0001$). Dunn multiple comparisons test indicated that mean ranks were lower in the No CVS siRNA ($P<0.0001$) and CVS GFP ($P<0.0001$) groups compared with No CVS GFP. Furthermore, the CVS siRNA circadian HR was increased relative to both No CVS siRNA ($P=0.0028$) and CVS GFP ($P=0.0004$).

Circadian and cumulative arterial pressures

To examine the effects of chronic stress and decreased IL output on long-term blood pressure regulation, home cage arterial pressures (Figure 3A, n=6–8/group) were continuously monitored. For mean arterial pressure (MAP), non-parametric analysis indicated significant group differences (Friedman statistic=28.9, $P<0.0001$). Multiple comparisons revealed increases in the CVS siRNA rats relative to No CVS siRNA ($P<0.0001$) and CVS GFP ($P=0.0013$). AUC analysis found that the CVS siRNA group experienced greater




Figure 2. Chronic stress led to no differences in circadian home cage activity ($n=7-8/\text{group}$) (A). Although, total activity counts were altered (see text). Circadian heart rate disruption occurred with siRNA, CVS, and CVS siRNA (B). Circadian heart rate was lower in the No CVS siRNA and CVS GFP groups compared with No CVS GFP. Furthermore, CVS siRNA circadian heart rate was increased relative to both No CVS siRNA and CVS GFP. **** $P<0.0001$ No CVS siRNA vs No CVS GFP, ††† $P<0.0001$ CVS GFP vs No CVS GFP, ††† $P<0.001$ CVS siRNA vs CVS GFP, §§ $P<0.01$ CVS siRNA vs No CVS siRNA. CVS, chronic variable stress; D, dark cycle; GFP, green fluorescent protein; L, light cycle; siRNA, small interfering RNA.

cumulative MAP ($P<0.0001$, Figure 3B) and systolic arterial pressure ($P<0.0001$, Figure 3C) than all other groups. Diastolic arterial pressure ($P<0.0001$, Figure 3D) was also elevated in the CVS siRNA animals compared with No CVS siRNA and CVS GFP. Between non-stressed rats, the siRNA treatment led to lower cumulative pressures (MAP, systolic arterial pressure, and diastolic arterial pressure, $P<0.0001$) relative to GFP.

Circadian and cumulative pulse pressure

Pulse pressure is a function of vascular stiffness and predicts heart disease independent of MAP.^{42,43} Friedman test of circadian pulse pressure (Figure 4A) identified significant group differences (Friedman statistic=39.74, $P<0.0001$). Mean ranks were higher in CVS GFP rats relative to No CVS GFP ($P=0.042$). Further, pulse pressure was elevated in the CVS siRNA rats compared with all other groups ($P<0.05$). Cumulative pulse pressure from AUC

analysis was increased in both CVS groups relative to No CVS ($P<0.0001$, Figure 4B). Additionally, CVS siRNA cumulative pulse pressure was greater than all groups, including CVS GFP ($P<0.0001$).

Acute stress reactivity

To study the role of the IL in acute stress reactivity, MAP and HR reactivity were monitored during restraint ($n=8/\text{group}$). During acute stress, 3-way repeated-measures ANOVA of HR reactivity found a main effect of time [$F(1, 84)=53.99$, $P<0.0001$] (Figure 5A). Compared with No CVS GFP, vGluT1 siRNA elevated HR during restraint minutes 15 to 25 ($P\leq 0.040$). Both CVS GFP and CVS siRNA rats had elevated HR compared with No CVS GFP from 10 to 25 minutes of restraint ($P\leq 0.006$). Further, CVS siRNA rats had elevated HR during restraint at 35 and 40 minutes ($P\leq 0.008$). While recovering from stress in the home cage, HR remained elevated in the CVS siRNA group relative to No CVS GFP at




Figure 3. Chronic stress and siRNA treatment ($n=8/\text{group}$) interacted leading to altered circadian mean arterial pressure (A). Analysis of cumulative arterial pressure indicated that CVS, only in siRNA-treated rats, increased chronic mean arterial pressure (B), systolic arterial pressure (C), and diastolic arterial pressure (D). * $P<0.05$ CVS siRNA vs No CVS siRNA, ** $P<0.01$ CVS siRNA vs No CVS siRNA, † $P<0.05$ CVS siRNA vs CVS GFP, †††† $P<0.0001$ CVS siRNA vs CVS GFP, ‡ $P<0.05$ No CVS siRNA vs No CVS GFP, § $P<0.05$ CVS siRNA vs No CVS GFP. AUC indicates area under the curve; CVS, chronic variable stress; D, dark cycle; GFP, green fluorescent protein; L, light cycle; siRNA, small interfering RNA.

minutes 45 and 95 ($P\leq 0.010$). Additionally, CVS GFP and No CVS siRNA had elevated HR on minutes 45 ($P=0.0003$) and 95 ($P=0.031$), respectively. Cumulative HR reactivity from AUC analysis of acute stress responses revealed that both No CVS siRNA and CVS GFP groups had elevated HR responses to acute restraint ($P<0.0001$, Figure 5B). Moreover, the CVS siRNA group experienced greater cumulative HR than all other groups ($P=0.0006$).

Analysis of stress-evoked MAP by 3-way repeated-measures ANOVA identified a main effect of time [$F(1, 84)=P<0.0001$] (Figure 5C). The CVS GFP group had greater MAP reactivity compared with No CVS GFP on minutes 5 to 15 of restraint ($P\leq 0.030$). The CVS siRNA animals had greater MAP than No CVS GFP at 15, 20, and 40 minutes ($P\leq 0.05$). During recovery, CVS GFP MAP remained elevated at 50, 75, and 80 minutes ($P\leq 0.04$); furthermore, CVS siRNA MAP was higher at minutes 75 to 90 ($P\leq 0.045$). AUC analysis by 2-way ANOVA found siRNA treatment increased cumulative MAP ($P<0.0001$, Figure 5D). CVS also increased MAP AUC as both CVS groups were higher than respective No CVS controls ($P<0.0001$).

Experiment 2

Injection placement

Similar to experiment 1, injections of lentiviral-packaged constructs were targeted to the IL with minimal spread to PL (Figure 6).⁴⁰ Although, injections from experiment 2 had greater spread into superficial layers of the IL. Additionally, some injections spread into the striatum caudally but this region does not exhibit vGluT1 expression.⁴⁴

Vascular function

To assess the vascular consequences of prolonged stress, arterial function was monitored in response to endothelial-dependent and -independent agents ex vivo. In terms of endothelial-dependent vasoconstriction, 3-way repeated-measures ANOVA identified a main effect of KCl concentration [$F(1,36)=669.73, P<0.0001$] and an interaction of drug concentration \times viral treatment [$F(1,36)=9.55, P=0.004$] (Figure 7A). As determined by post-hoc analyses, aortas of CVS siRNA animals constricted less than No CVS GFP at KCl concentrations >25 mmol/L ($P\leq 0.0006$). CVS siRNA also




Figure 4. Chronic stress as well as CVS siRNA increased circadian pulse pressure (A). Cumulative pulse pressure was increased in CVS exposed rats, with CVS siRNA rats experiencing the greatest chronic pulse pressure (B). * $P < 0.05$ CVS GFP vs No CVS GFP, † $P < 0.05$ CVS siRNA vs No CVS GFP, †††† $P < 0.0001$ CVS siRNA vs No CVS GFP, ‡ $P < 0.05$ CVS siRNA vs No CVS siRNA, †††† $P < 0.0001$ CVS siRNA vs No CVS siRNA, § $P < 0.05$ CVS siRNA vs CVS GFP. AUC indicates area under the curve; CVS, chronic variable stress; D, dark cycle; GFP, green fluorescent protein; L, light cycle; siRNA, small interfering RNA.

showed impaired constriction compared with CVS GFP at concentrations >30 mmol/L ($P \leq 0.006$). Compared with No CVS siRNA, CVS siRNA vasoreactivity was decreased at concentrations of 30 and 50 mmol/L ($P \leq 0.042$). Within the No CVS groups, siRNA treatment decreased constriction at 40 mmol/L ($P = 0.019$). Endothelium-independent vasoconstriction in response to phenylephrine showed a main effect of concentration [$F(1,40) = 31.62$, $P < 0.0001$] (Figure 7B). Either siRNA or CVS alone impaired vasoreactivity at drug concentrations >1 $\mu\text{mol/L}$ ($P < 0.05$). However, CVS siRNA animals had impaired vasoconstriction compared with all other groups at phenylephrine concentrations >0.1 $\mu\text{mol/L}$ ($P < 0.05$).

Endothelial-dependent vasorelaxation to acetylcholine showed a main effect of drug concentration [$F(1,40) = 15.89$, $P = 0.0003$] by 3-way repeated-measures ANOVA (Figure 7C). Post-test found that CVS siRNA vasorelaxation was decreased compared with all groups at acetylcholine concentrations >1 $\mu\text{mol/L}$ ($P = 0.048$). Endothelial-independent vasorelaxation to sodium nitroprusside, as analyzed by 3-way repeated-measures ANOVA, showed a main effect of sodium nitroprusside concentration [$F(1,44) = 12.65$, $P = 0.0009$] (Figure 7D). CVS siRNA tissue had impaired vasorelaxation compared with both No CVS groups at concentrations >0.03 $\mu\text{mol/L}$ ($P = 0.026$). Additionally, CVS alone impaired vasorelaxation in GFP rats at sodium nitroprusside concentrations >0.3 $\mu\text{mol/L}$ ($P < 0.010$).

Vascular and cardiac histology

Histological analysis was performed to investigate the effects of chronic stress and vGluT1 knockdown on markers of vascular and cardiac pathology (Table 2). In GFP-injected rats, CVS increased aortic tunica media thickness [$F(1,24) = 18.55$, $P = 0.0002$] and media:lumen area [$F(1,24) = 10.45$, $P < 0.004$].

Furthermore, CVS increased adventitial fibrosis in terms of increased collagen density [$F(1,24) = 4.944$, $P = 0.036$]. Chronic stress also affected the myocardium by increasing heart weight [$F(1,24) = 7.028$, $P = 0.014$] and myocyte surface area [$F(1,23) = 5.084$, $P = 0.034$]. In animals with reduced vGluT1, CVS had greater effects on aortic remodeling. CVS siRNA rats had decreased luminal circumference [$F(1,24) = 8.217$, $P = 0.022$] and area [$F(1,24) = 8.142$, $P = 0.026$], increased media thickness [$F(1,24) = 18.55$, $P = 0.026$] and media:lumen area [$F(1,24) = 10.45$, $P < 0.0004$], increased collagen density [$F(1,24) = 4.944$, $P = 0.036$], and decreased adventitial thickness [$F(1,24) = 6.517$, $P = 0.031$] (Figure 8A through 8D). Collectively, these results indicate that CVS interacts with decreased IL function to promote fibrosis and inward remodeling of vascular muscle leading to restricted luminal area, potentially accounting for impaired vasoreactivity and arterial stiffness. CVS siRNA rats also exhibited cardiac hypertrophy as these animals had increased heart weight [$F(1,24) = 7.028$, $P = 0.014$], heart weight relative to body weight [$F(1,24) = 17.09$, $P = 0.015$], and increased myocyte surface area [$F(1,23) = 5.084$, $P = 0.034$] (Figure 8E and 8F), without affecting myocardial collagen deposition.

Discussion

In the current study, we used viral-mediated gene transfer to decrease IL glutamatergic output while simultaneously monitoring hemodynamic, vascular, and cardiac responses to chronic stress. We found that IL vGluT1 knockdown increased heart rate and arterial pressure reactivity to acute stress. Additionally, IL hypofunction during CVS increased chronic home cage arterial pressure. These changes were accompanied by both endothelial-independent and -dependent arterial dysfunction. Histological analysis revealed that animals

experiencing CVS with decreased IL output also had inward vascular remodeling, fibrosis, and cardiac hypertrophy. Collectively, these results indicate that IL projection neurons are critical for reducing acute cardiovascular stress reactivity, long-term arterial pressure, and vascular endothelial dysfunction. Furthermore, they identify a neurochemical mechanism linking stress appraisal and emotion with chronic stress-induced autonomic dysfunction.

Epidemiological evidence indicates that prolonged stress is a major risk factor for cardiovascular illness and mortality.^{7,45} Additionally, numerous clinical studies point to enhanced stress reactivity as a marker of future cardiovascular pathology.^{9,46} Rodent studies using repeated-stress models of depression (chronic variable stress, chronic mild stress, chronic social defeat, etc.) have found alterations in baroreflex function, decreased heart rate variability, and ventricular arrhythmias.^{4,47–53} Given the strong association between

prolonged stress/emotional disorders and cardiovascular disease,^{54–56} it is important to identify the specific neural processes of stress appraisal and mood that impact cardiovascular function. Emerging evidence suggests that autonomic imbalance prolongs exposure to neural and endocrine stress mediators, generating risk for cardiovascular pathology.^{57–59} Stress-associated molecules such as corticosteroids, corticotropin-releasing hormone, and neuropeptide Y, among others, have been shown to affect cardiovascular function in animal models.^{51,60,61} However, the neural circuits that integrate cognitive appraisal and autonomic balance remain to be determined.

The contribution of the current study relates to the site-specific genetic approach that reduces IL vGluT1 expression long-term.²⁸ Given the decreased output from a critical cognitive/emotional region,^{11,32} we monitored both stress-induced and resting parameters of heart rate and arterial




Figure 5. In response to acute restraint, both siRNA and CVS ($n=8$ /group) increased heart rate reactivity and impaired recovery (A). Cumulative acute heart rate responses were also elevated by siRNA and CVS, but CVS siRNA rats had the greatest overall heart rate response (B). Chronically stressed rats, both GFP and siRNA treated, had increased mean arterial pressure reactivity and impaired recovery (C). Analysis of cumulative restraint-induced pressor responses indicated effects of both siRNA and CVS (D). * $P<0.05$ CVS GFP vs No CVS GFP, † $P<0.05$ CVS siRNA vs No CVS GFP, ‡ $P<0.05$ No CVS siRNA vs No CVS GFP, § $P<0.05$ CVS siRNA vs No CVS siRNA, †§ $P<0.05$ CVS siRNA vs CVS GFP. AUC indicates area under the curve; CVS, chronic variable stress; GFP, green fluorescent protein; siRNA, small interfering RNA.




Figure 6. The spread of individual lentiviral injections was traced on photomicrographs and overlaid onto atlas templates from Swanson⁴⁰ to depict the localization of vesicular glutamate transporter 1 knockdown in experiment 2. White arrows indicate dorsal and ventral boundaries of the IL. Numbers indicate distance rostral to bregma in millimeters. AC indicates anterior cingulate; IL, infralimbic cortex; PL, prelimbic cortex.

pressure in otherwise unstressed rats, as well as rats experiencing the cumulative burden of chronic stress exposure. This approach was followed by *ex vivo* analysis of arterial function and histological investigation of vascular and myocardial structure. These studies found several siRNA effects in animals that did not experience CVS (Table 3). The knockdown increased HR and MAP reactivity to acute restraint and impaired endothelial-independent vasoconstriction, suggesting hypofunction of IL primes for enhanced cardiovascular reactivity and impaired vasomotor function. Previous studies indicating that N-methyl-D-aspartate (NMDA)-mediated activation of the IL reduces tachycardic and pressor responses to acute air-jet stress further support the

conclusion that IL glutamate output reduces acute cardiovascular reactivity.⁶² Paradoxically, No CVS siRNA animals exhibited decreased resting home cage circadian heart rate and arterial pressure. This effect may relate to the important role of IL molecular clocks in coordinating circadian physiological rhythms.⁶³ In GFP-treated rats, CVS dampened home cage activity, decreasing circadian rhythms of activity and potentially accounting for effects of CVS to decrease circadian HR. Interestingly, CVS did not alter chronic home cage MAP; however, CVS-exposed animals exhibited enhanced tachycardic and pressor responses to acute restraint; this was accompanied by impaired endothelial-independent vasorelaxation and constriction. Furthermore, CVS increased pulse pressure, vascular smooth muscle thickness and fibrosis, as well as cardiomyocyte surface area.

The effects of vGluT1 knockdown and CVS interacted to generate a phenotype of enhanced cardiovascular risk. All measures of arterial pressure, both acute stress-induced and chronic home cage, were elevated. This group also had impairment of both endothelial-dependent and -independent vascular dilation and constriction. The overall risk profile was further evident by inward remodeling of the vasculature attributable to hypertrophy and fibrosis that reduced luminal area, indicative of vascular stiffness. Additionally, these rats exhibited myocardial hypertrophy including increased myocyte size, heart weight, and body weight-corrected heart weight. It is worth noting that some effects in the CVS siRNA group result from comparisons to No CVS GFP. In the case of histological measures, there were no significant differences between CVS GFP and CVS siRNA animals. This suggests that the structural changes observed are not sufficient to fully account for vascular dysfunction in the CVS siRNA group relative to CVS GFP. Furthermore, home cage arterial pressure elevations were modest and not indicative of a hypertensive state. More likely, endothelial dysfunction after chronic stress in animals with impaired IL function results from the interaction of multiple factors, including enhanced hypothalamic-pituitary-adrenal axis activity, elevated cardiovascular reactivity, increased resting arterial pressure, and vascular remodeling. Taken together, these results suggest that conditions associated with decreased ventral mPFC activity, including depression, anxiety, and post-traumatic stress disorder,³² may enhance vulnerability to the effects of prolonged stress on cardiovascular health.

The specific circuit mechanisms downstream of IL glutamate release that account for the current findings remain to be determined. Although the IL does not directly innervate either pre-ganglionic autonomic neurons or neurosecretory cells of the hypothalamus,^{21,64} the region has widespread projections throughout the forebrain and brainstem.^{21,25} Inputs to the posterior hypothalamus target local inhibitory cells,²³ providing a potential pathway to inhibit




Figure 7. Aortic tissue from CVS siRNA animals ($n=7$ /group) had impaired endothelial-dependent vasoconstriction (**A**). Both CVS and siRNA impaired endothelial-independent vasoreactivity but the CVS siRNA group had the greatest impairment (**B**). Endothelial-dependent vasorelaxation was impaired only in the CVS siRNA group (**C**), while endothelial-independent relaxation was impaired in CVS GFP and CVS siRNA tissue (**D**). * $P<0.05$ CVS siRNA vs No CVS GFP, † $P<0.05$ CVS siRNA vs No CVS siRNA, ‡ $P<0.05$ CVS siRNA vs CVS GFP, § $P<0.05$ No CVS siRNA vs No CVS GFP, †† $P<0.05$ CVS GFP vs No CVS GFP. CVS indicates chronic variable stress; GFP, green fluorescent protein; M, molar; siRNA, small interfering RNA.

stress reactivity.⁶⁵ Additionally, IL-targeted neurons of the PH innervate the paraventricular hypothalamus, a region important for vasomotor tone.^{23,66} There are also IL

projections to brainstem cardio regulatory centers including the nucleus of the solitary tract and the rostral and caudal regions of the ventrolateral medulla that may regulate

Table 2. Vascular and Cardiac Histological Analysis

n=7/Group	No CVS GFP	No CVS siRNA	CVS GFP	CVS siRNA
Luminal Circumference, mm	4.967±0.058	5.135±0.058	4.897±0.069	4.893±0.019*
Luminal area, mm ²	1.694±0.035	1.786±0.037	1.619±0.037	1.550±0.089*
Media thickness, mm	0.107±0.001	0.108±0.002	0.113±0.001†	0.114±0.001*‡
Media:lumen area	0.341±0.009	0.335±0.014	0.381±0.005†	0.392±0.024*‡
Adventitia collagen (% area)	66.930±1.320	66.820±0.893	71.49±0.313†	70.86±0.659*‡
Adventitia thickness, mm	0.040±0.001	0.037±0.002	0.036±0.002	0.034±0.001‡
Heart weight, g	1.264±0.018	1.266±0.038	1.321±0.028†	1.365±0.025*‡
Heart weight/body weight (×100)	0.335±0.005	0.340±0.009	0.355±0.007	0.366±0.007‡
Myocyte surface area, μm ²	349.930±18.701	352.091±11.664	396.888 ±18.842†	406.841±8.527*‡
Myocardial collagen (% area)	0.429±0.013	0.449±0.023	0.479±0.042	0.459±0.016

Histological quantification of vascular and myocardial structure. Dimensions of the lumen and media were quantified from elastin staining. Adventitial size and fibrosis were determined from collagen staining. Myocyte surface area was measured with membrane labeling and cardiac fibrosis was queried via collagen staining. There were no effects of small interfering RNA alone. Chronic variable stress increased media thickness, adventitial collagen, and myocyte size. In contrast, CVS siRNA tissue exhibited alterations in all structural end points assessed except myocardial fibrosis. CVS indicates chronic variable stress; GFP, green fluorescent protein; siRNA, small interfering RNA.

* $P<0.05$ CVS siRNA vs No CVS siRNA; † $P<0.05$ CVS GFP vs No CVS GFP, ‡ $P<0.05$ CVS siRNA vs No CVS GFP.




Figure 8. Verhoeff-van Gieson stain was used to visualize elastin (dark brown) in aortic tissue of No CVS GFP (A) and CVS siRNA (B) rats. Greater thickness of the tunica media is indicated by white arrows. Masson Trichrome was used to stain collagen (blue) in aortic tissue of No CVS GFP (C) and CVS siRNA (D) animals. White arrows indicate increased collagen density in the tunica adventitia. Wheat germ agglutinin conjugated to Alexa 488 (green) was used to visualize cardiomyocyte membranes (E). Binarized myocyte images (F) were used to quantify myocyte surface area. Scale bars: (A through D) 50 μm , (E) 10 μm . *Denotes the lumen.

autonomic outflow.^{24,67} Furthermore, there is a complex network of local cortical circuitry, including interneurons in the IL, that mediates the overall activity of glutamatergic projection neurons.⁶⁸ Based on the current findings, these local circuits would be expected to play a role in autonomic reactivity. Ultimately, projection-specific analyses are needed to isolate the precise cell populations within IL glutamate neurons that reduce autonomic imbalance after chronic stress.

While these studies identified a novel frontal cortical node for preventing the deleterious cardiovascular effects of chronic stress, there are limitations worth discussing. First, the current studies were limited to males. As depression-cardiovascular comorbidity has at least twice the prevalence in females,^{69–71} it is important to consider sex-specific regulation. Interestingly, a recent study investigating vascular function in female rodents after chronic stress actually found

Table 3. siRNA and/or CVS Effects From Experiments 1 and 2

	siRNA	CVS	siRNA+CVS
Activity (15 day total counts)	↔	↓*	↑*,†,‡
HR (15 d)	↓*	↓*	↑†,‡
MAP (15-d AUC)	↓*	↔	↑*,†,‡
SAP (15-d AUC)	↓*	↔	↑*,†,‡
DAP (15-d AUC)	↓*	↔	↑*,†
Pulse pressure (15-d AUC)	↔	↑*	↑*,†,‡
HR (acute stress)	↑*	↑*	↑*,†,‡
MAP (acute stress)	↑*	↑*	↑*,†
Vasoconstriction (ED)	↔	↔	↓*,†,‡
Vasoconstriction (EI)	↓*	↓*	↓*,†,‡
Vasorelaxation (ED)	↔	↔	↓*,†,‡
Vasorelaxation (EI)	↔	↓*	↓*,†
Lumen circumference	↔	↔	↓†
Luminal area	↔	↔	↓†
Media Thickness	↔	↑*	↑*,†
Media:lumen area	↔	↑*	↑*,†
Adventitia thickness	↔	↔	↓*
Adventitia collagen	↔	↑*	↑*,†
Heart weight	↔	↑*	↑*,†
Heart weight/body weight	↔	↔	↑*
Myocardial collagen	↔	↔	↔
Myocyte surface area	↔	↑*	↑*,†

Integrative summary of all data reported in terms of small interfering RNA effects, chronic stress effects, and the combination of small interfering RNA and chronic variable stress. Arrows indicate significant small interfering RNA and/or chronic variable stress effects. AUC indicates area under the curve; CVS, chronic variable stress; DAP, diastolic arterial pressure; ED, endothelial-dependent; EI, endothelial-independent; HR, heart rate; MAP, mean arterial pressure; SAP, systolic arterial pressure; siRNA, small interfering RNA. * $P < 0.05$ vs No CVS GFP, † $P < 0.05$ vs No CVS siRNA, ‡ $P < 0.05$ vs CVS GFP.

that ovarian hormones protect against stress-induced arterial dysfunction.⁷² Comparing the neural basis of pathological responses in males and females would likely yield a better understanding of the disproportionate female impact of mood disorder-cardiovascular comorbidity. In regards to the vGluT1 siRNA, this approach reduces vGluT1 mRNA and protein²⁸; although, we have not directly measured glutamate release from IL synaptic terminals. However, the synaptic consequences of global vGluT1 deletion have been studied extensively in mice.^{29,30} These studies indicate that vGluT1 expression levels dictate vesicular glutamate load and post-synaptic excitation. Further, complete deletion of vGluT1 leads to the docking and fusion of empty vesicles, preventing excitatory post-synaptic currents.²⁹ Another consideration is that the current vasoreactivity experiments were performed in thoracic aorta. Although the results identified impaired function and indicators of stiffness, the aorta is a conductive

artery and future experiments with resistance arterioles might yield differing results. Indeed, these studies could show greater effects as resistance arteries receive more sympathetic innervation.^{73,74} Furthermore, investigating vascular resistance could yield data with significant relevance for stress-related hypertension.

The current findings highlight IL glutamatergic neurons as a node of integration that links stress appraisal with hemodynamic reactivity, long-term arterial pressure control, and vascular endothelial function. These results also indicate that, in the context of chronic stress, cortical cells mediating cognition and behavior can impact the structure and function of the heart and vasculature. Future research investigating the mechanisms that regulate IL projection neuron activity and the downstream post-synaptic events activated by IL glutamate release may yield insight into novel targets to prevent or reduce the burden of cardiovascular disease.

Acknowledgments

Cincinnati Children's Hospital Medical Center Research Pathology Core performed cardiac and vascular histological processing. This article was first published as a preprint: Schaeuble, Packard, McKlveen, Morano, Fourman, Smith, Scheimann, Packard, Wilson, James, Hui, Ulrich-Lai, Herman, Myers. Prefrontal cortical regulation of chronic stress-induced cardiovascular susceptibility. *bioRxiv*. doi.org/10.1101/675835. Dr McKlveen contributed to this article in her personal capacity. The views expressed herein are those of the authors and do not necessarily represent the views of the National Institutes of Health, National Center for Complementary and Integrative Health, or the United States Government.

Sources of Funding

This work was supported by National Institutes of Health grants K99/R00 HL122454 to Myers and R01 MH049698 to Herman.

Disclosures

None.

References

- de Kloet ER, Joëls M, Holsboer F. Stress and the brain: from adaptation to disease. *Nat Rev Neurosci*. 2005;6:463–475.
- Myers B, McKlveen JM, Herman JP. Glucocorticoid actions on synapses, circuits, and behavior: implications for the energetics of stress. *Front Neuroendocrinol*. 2014;35:180–196.
- Wardle J, Chida Y, Gibson EL, Whitaker KL, Steptoe A. Stress and adiposity: a meta-analysis of longitudinal studies. *Obesity*. 2011;19:771–778.
- Grippe AJ, Johnson AK. Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models. *Stress*. 2009;12:1–21.
- Binder EB, Nemeroff CB. The CRF system, stress, depression and anxiety—insights from human genetic studies. *Mol Psychiatry*. 2010;15:574–588.

6. Sgoifo A, Carnevali L, Pico Alfonso MDLA, Amore M. Autonomic dysfunction and heart rate variability in depression. *Stress*. 2015;18:343–352.
7. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*. 2004;364:937–952.
8. Barefoot JC, Helms MJ, Mark DB, Blumenthal JA, Califf RM, Haney TL, O'Connor CM, Siegler IC, Williams RB. Depression and long-term mortality risk in patients with coronary artery disease. *Am J Cardiol*. 1996;78:613–617.
9. Chida Y, Steptoe A. Greater cardiovascular responses to laboratory mental stress are associated with poor subsequent cardiovascular risk status. *Hypertension*. 2010;55:1026–1032.
10. Myers-Schulz B, Koenigs M. Functional anatomy of ventromedial prefrontal cortex: implications for mood and anxiety disorders. *Mol Psychiatry*. 2012;17:132–141.
11. McKlveen JM, Myers B, Herman JP. The medial prefrontal cortex: coordinator of autonomic, neuroendocrine and behavioural responses to stress. *J Neuroendocrinol*. 2015;27:446–456.
12. Damasio AR. The somatic marker hypothesis and the possible functions of the prefrontal cortex. *Philos Trans R Soc Lond B Biol Sci*. 1996;351:1413–1420.
13. Wood JN, Grafman J. Human prefrontal cortex: processing and representational perspectives. *Nat Rev Neurosci*. 2003;4:139–147.
14. Liotti M, Mayberg HS, Brannan SK, McGinnis S, Jerabek P, Fox PT. Differential limbic-cortical correlates of sadness and anxiety in healthy subjects: implications for affective disorders. *Biol Psychiatry*. 2000;48:30–42.
15. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwab JM, Kennedy SH. Deep brain stimulation for treatment-resistant depression. *Neuron*. 2005;45:651–660.
16. Shoemaker JK, Badrov MB, Al-Khazraji BK, Jackson DN. Neural control of vascular function in skeletal muscle. In: Hoboken NJ, ed. *Compr Physiol*. 2015;6:303–329. DOI:10.1002/cphy.c150004.
17. Beissner F, Meissner K, Bär K-J, Napadow V. The autonomic brain: an activation likelihood estimation meta-analysis for central processing of autonomic function. *J Neurosci*. 2013;33:10503–10511.
18. Gianaros PJ, Sheu LK. A review of neuroimaging studies of stressor-evoked blood pressure reactivity: emerging evidence for a brain-body pathway to coronary heart disease risk. *NeuroImage*. 2009;47:922–936.
19. Gianaros PJ, Wager TD. Brain-body pathways linking psychological stress and physical health. *Curr Dir Psychol Sci*. 2015;24:313–321.
20. Uylings HBM, Groenewegen HJ, Kolb B. Do rats have a prefrontal cortex? *Behav Brain Res*. 2003;146:3–17.
21. Vertes RP. Differential projections of the infralimbic and prelimbic cortex in the rat. *Synapse*. 2004;51:32–58.
22. Öngür D, Ferry AT, Price JL. Architectonic subdivision of the human orbital and medial prefrontal cortex. *J Comp Neurol*. 2003;460:425–449.
23. Myers B, Carvalho-Netto E, Wick-Carlson D, Wu C, Naser S, Solomon MB, Ulrich-Lai YM, Herman JP. GABAergic signaling within a limbic-hypothalamic circuit integrates social and anxiety-like behavior with stress reactivity. *Neuropsychopharmacology*. 2016;41:1530–1539.
24. Gabbott PLA, Warner TA, Jays PRL, Salway P, Busby SJ. Prefrontal cortex in the rat: projections to subcortical autonomic, motor, and limbic centers. *J Comp Neurol*. 2005;492:145–177.
25. Wood M, Adil O, Wallace T, Fourman S, Wilson SP, Herman JP, Myers B. Infralimbic prefrontal cortex structural and functional connectivity with the limbic forebrain: a combined viral genetic and optogenetic analysis. *Brain Struct Funct*. 2019;224:73–97.
26. Myers B, Mark Dolgas C, Kasckow J, Cullinan WE, Herman JP. Central stress-integrative circuits: forebrain glutamatergic and GABAergic projections to the dorsomedial hypothalamus, medial preoptic area, and bed nucleus of the stria terminalis. *Brain Struct Funct*. 2014;219:1287–1303.
27. Smith BL, Lyons CE, Correa FG, Benoit SC, Myers B, Solomon MB, Herman JP. Behavioral and physiological consequences of enrichment loss in rats. *Psychoneuroendocrinology*. 2017;77:37–46.
28. Myers B, McKlveen JM, Morano R, Ulrich-Lai YM, Solomon MB, Wilson SP, Herman JP. Vesicular glutamate transporter 1 knockdown in infralimbic prefrontal cortex augments neuroendocrine responses to chronic stress in male rats. *Endocrinology*. 2017;158:3579–3591.
29. Schuske K, Jorgensen EM. Vesicular glutamate transporter–shooting blanks. *Science*. 2004;304:1750–1752.
30. Wojcik SM, Rhee JS, Herzog E, Sigler A, Jahn R, Takamori S, Brose N, Rosenmund C. An essential role for vesicular glutamate transporter 1 (VGLUT1) in postnatal development and control of quantal size. *Proc Natl Acad Sci USA*. 2004;101:7158–7163.
31. Grillo CA, Piroli GG, Lawrence RC, Wrihten SA, Green AJ, Wilson SP, Sakai RR, Kelly SJ, Wilson MA, Mott DD, Reagan LP. Hippocampal insulin resistance impairs spatial learning and synaptic plasticity. *Diabetes*. 2015;64:3927–3936.
32. McKlveen JM, Myers B, Flak JN, Bundzikova J, Solomon MB, Seroogy KB, Herman JP. Role of prefrontal cortex glucocorticoid receptors in stress and emotion. *Biol Psychiatry*. 2013;74:672–679.
33. Grillo CA, Tamashiro KL, Piroli GG, Melhorn S, Gass JT, Newsom RJ, Reznikov LR, Smith A, Wilson SP, Sakai RR, Reagan LP. Lentivirus-mediated downregulation of hypothalamic insulin receptor expression. *Physiol Behav*. 2007;92:691–701.
34. Flak JN, Jankord R, Solomon MB, Krause EG, Herman JP. Opposing effects of chronic stress and weight restriction on cardiovascular, neuroendocrine and metabolic function. *Physiol Behav*. 2011;104:228–234.
35. Goodson ML, Packard AEB, Buesing DR, Maney M, Myers B, Fang Y, Basford JE, Hui DY, Ulrich-Lai YM, Herman JP, Ryan KK. Chronic stress and Rosiglitazone increase indices of vascular stiffness in male rats. *Physiol Behav*. 2017;172:16–23.
36. Flak JN, Solomon MB, Jankord R, Krause EG, Herman JP. Identification of chronic stress-activated regions reveals a potential recruited circuit in rat brain. *Eur J Neurosci*. 2012;36:2547–2555.
37. Basford JE, Koch S, Anjak A, Singh VP, Krause EG, Robbins N, Weintraub NL, Hui DY, Rubinstein J. Smooth muscle LDL receptor-related protein-1 deletion induces aortic insufficiency and promotes vascular cardiomyopathy in mice. *PLoS One*. 2013;8:e82026.
38. Gupta MK, McLendon PM, Gulick J, James J, Khalili K, Robbins J. UBC9-mediated sumoylation favorably impacts cardiac function in compromised hearts. *Circ Res*. 2016;118:1894–1905.
39. Bensley JG, De Matteo R, Harding R, Black MJ. Three-dimensional direct measurement of cardiomyocyte volume, nuclearity, and ploidy in thick histological sections. *Sci Rep*. 2016;6:23756.
40. Swanson LW. *Brain Maps: Structure of the Rat Brain*, 3rd ed. Los Angeles, CA: Academic Press; 2004:1–215.
41. Solomon MB, Jones K, Packard BA, Herman JP. The medial amygdala modulates body weight but not neuroendocrine responses to chronic stress. *J Neuroendocrinol*. 2010;22:13–23.
42. Glasser SP, Halberg DL, Sands C, Gamboa CM, Muntner P, Safford M. Is pulse pressure an independent risk factor for incident acute coronary heart disease events? The REGARDS study. *Am J Hypertens*. 2014;27:555–563.
43. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. *Circulation*. 1999;100:354–360.
44. Ziegler DR, Cullinan WE, Herman JP. Distribution of vesicular glutamate transporter mRNA in rat hypothalamus. *J Comp Neurol*. 2002;448:217–229.
45. Steptoe A, Kivimäki M. Stress and cardiovascular disease. *Nat Rev Cardiol*. 2012;9:360–370.
46. Vogelzangs N, Beekman ATF, Milaneschi Y, Bandinelli S, Ferrucci L, Penninx BWJH. Urinary cortisol and six-year risk of all-cause and cardiovascular mortality. *J Clin Endocrinol Metab*. 2010;95:4959–4964.
47. Grippio AJ, Moffitt JA, Johnson AK. Cardiovascular alterations and autonomic imbalance in an experimental model of depression. *Am J Physiol Integr Comp Physiol*. 2002;282:R1333–R1341.
48. Costoli T, Bartolomucci A, Graiani G, Stilli D, Laviola G, Sgoifo A. Effects of chronic psychosocial stress on cardiac autonomic responsiveness and myocardial structure in mice. *Am J Physiol Heart Circ Physiol*. 2004;286:H2133–H2140.
49. Carnevali L, Trombini M, Rossi S, Graiani G, Manghi M, Koolhaas JM, Quaini F, Macchi E, Nalivaiko E, Sgoifo A. Structural and electrical myocardial remodeling in a rodent model of depression. *Psychosom Med*. 2013;75:42–51.
50. Wood SK. Cardiac autonomic imbalance by social stress in rodents: understanding putative biomarkers. *Front Psychol*. 2014;5:950.
51. Wood SK, McFadden KV, Grigoriadis D, Bhatnagar S, Valentino RJ. Depressive and cardiovascular disease comorbidity in a rat model of social stress: a putative role for corticotropin-releasing factor. *Psychopharmacology*. 2012;222:325–336.
52. Duarte JO, Planeta CS, Crestani CC. Immediate and long-term effects of psychological stress during adolescence in cardiovascular function: comparison of homotypic vs heterotypic stress regimens. *Int J Dev Neurosci*. 2015;40:52–59.

53. Crestani CC. Emotional stress and cardiovascular complications in animal models: a review of the influence of stress type. *Front Physiol*. 2016;7:251.
54. Barton DA, Dawood T, Lambert EA, Esler MD, Haikerwal D, Brenchley C, Socratous F, Kaye DM, Schlaich MP, Hickie I, Lambert GW. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? *J Hypertens*. 2007;25:2117–2124.
55. Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, Czajkowski SM, O'Connor C, Stone PH, Freedland KE. Depression, heart rate variability, and acute myocardial infarction. *Circulation*. 2001;104:2024–2028.
56. Hausberg M, Hillebrand U, Kisters K. Addressing sympathetic overactivity in major depressive disorder. *J Hypertens*. 2007;25:2004–2005.
57. Johnson AK, Grippo AJ. Sadness and broken hearts: neurohumoral mechanisms and co-morbidity of ischemic heart disease and psychological depression. *J Physiol Pharmacol*. 2006;5–29.
58. Thayer JF, Åhs F, Fredrikson M, Sollers JJ, Wager TD. A meta-analysis of heart rate variability and neuroimaging studies: implications for heart rate variability as a marker of stress and health. *Neurosci Biobehav Rev*. 2012;36:747–756.
59. Wulsin LR, Horn PS, Perry JL, Massaro JM, D'Agostino RB. Autonomic imbalance as a predictor of metabolic risks, cardiovascular disease, diabetes, and mortality. *J Clin Endocrinol Metab*. 2015;100:2443–2448.
60. Oakley RH, Cruz-Topete D, He B, Foley JF, Myers PH, Xu X, Gomez-Sanchez CE, Chambon P, Willis MS, Cidlowski JA. Cardiomyocyte glucocorticoid and mineralocorticoid receptors directly and antagonistically regulate heart disease in mice. *Sci Signal*. 2019;12:eaa9685.
61. Costoli T, Sgoifo A, Stilli D, Flugge G, Adriani W, Laviola G, Fuchs E, Pedrazzini T, Musso E. Behavioural, neural and cardiovascular adaptations in mice lacking the NPY Y1 receptor. *Neurosci Biobehav Rev*. 2005;29:113–123.
62. Müller-Ribeiro FC, Zaretsky DV, Zaretskaia MV, Santos RAS, DiMicco JA, Fontes MAP. Contribution of infralimbic cortex in the cardiovascular response to acute stress. *Am J Physiol Regul Integr Comp Physiol*. 2012;303:R639–R650.
63. Woodruff ER, Chun LE, Hinds LR, Spencer RL. Diurnal corticosterone presence and phase modulate clock gene expression in the male rat prefrontal cortex. *Endocrinology*. 2016;157:1522–1534.
64. Saper CB, Loewy AD, Swanson LW, Cowan WM. Direct hypothalamo-autonomic connections. *Brain Res*. 1976;117:305–312.
65. Lisa M, Marmo E, Wible JH, DiMicco JA. Injection of muscimol into posterior hypothalamus blocks stress-induced tachycardia. *Am J Physiol*. 1989;257:R246–R251.
66. Zhou JJ, Ma HJ, Shao J, Wei Y, Zhang X, Zhang Y, Li DP. Downregulation of orexin receptor in hypothalamic paraventricular nucleus decreases blood pressure in obese Zucker rats. *J Am Heart Assoc*. 2019;8:e011434. DOI: 10.1161/JAHA.118.011434.
67. Myers B. Corticolimbic regulation of cardiovascular responses to stress. *Physiol Behav*. 2017;172:49–59.
68. McKlveen JM, Moloney RD, Scheimann JR, Myers B, Herman JP. 'Braking' the prefrontal cortex: the role of glucocorticoids and interneurons in stress adaptation and pathology. *Biol Psychiatry*. 2019;86:669–681.
69. Möller-Leimkühler AM. Gender differences in cardiovascular disease and comorbid depression. *Dialogues Clin Neurosci*. 2007;9:71–83.
70. Tobet SA, Handa RJ, Goldstein JM. Sex-dependent pathophysiology as predictors of comorbidity of major depressive disorder and cardiovascular disease. *Pflügers Arch*. 2013;465:585–594.
71. Pimple P, Lima BB, Hammadah M, Wilmot K, Ramadan R, Levantsevych O, Sullivan S, Kim JH, Kaseer B, Shah AJ, Ward L, Raggi P, Bremner JD, Hanfelt J, Lewis T, Quyyumi AA, Vaccarino V. Psychological distress and subsequent cardiovascular events in individuals with coronary artery disease. *J Am Heart Assoc*. 2019;8:e011866. DOI: 10.1161/JAHA.118.011866.
72. Brooks SD, Hileman SM, Chantler PD, Milde SA, Lemaster KA, Frisbee SJ, Shoemaker JK, Jackson DN, Frisbee JC. Protection from vascular dysfunction in female rats with chronic stress and depressive symptoms. *Am J Physiol Circ Physiol*. 2018;314:H1070–H1084.
73. Hao Z, Jiang X, Sharafeih R, SHEN S, Hand AR, Cone RE, O'Rourke J. Stimulated release of tissue plasminogen activator from artery wall sympathetic nerves: implications for stress-associated wall damage. *Stress*. 2005;8:141–149.
74. Brown IAM, Diederich L, Good ME, DeLalio LJ, Murphy SA, Cortese-Krott MM, Hall JL, Le TH, Isakson BE. Vascular smooth muscle remodeling in conductive and resistance arteries in hypertension. *Arterioscler Thromb Vasc Biol*. 2018;38:1969–1985.